Tilray Brands, Inc. (TLRY)
| Market Cap | 1.05B |
| Revenue (ttm) | 837.32M |
| Net Income (ttm) | -2.11B |
| Shares Out | 106.07M |
| EPS (ttm) | -20.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,922,668 |
| Open | 9.05 |
| Previous Close | 9.18 |
| Day's Range | 8.88 - 9.87 |
| 52-Week Range | 3.51 - 23.20 |
| Beta | 2.11 |
| Analysts | Buy |
| Price Target | 150.00 (+1,410.57%) |
| Earnings Date | Jan 8, 2026 |
About TLRY
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the c... [Read more]
Financial Performance
In 2025, Tilray Brands's revenue was $821.31 million, an increase of 4.10% compared to the previous year's $788.94 million. Losses were -$2.19 billion, 792.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TLRY stock is "Buy." The 12-month stock price target is $150.0, which is an increase of 1,410.57% from the latest price.
News
International Cannabis Expansion Gives Tilray Positive 2026 Outlook
Tilray reported financial performance for Q2-2026 with international sales driving growth. Tilray remains undervalued after its reverse split and after the rally over rescheduling subsided. Tilray for...
Marijuana industry taking fight against Wall Street blockades straight to Trump
Bankers have argued that Pot Inc.'s far-bigger prospective business – recreational use that would include the smoking of joints and ingesting high-inducing gummies – wasn't specifically addressed by t...
Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript
Tilray Brands, Inc. (TLRY) Q2 2026 Earnings Call Transcript
Tilray Stock Fires Up After Record Q2 Earnings: Here's Why
Tilray Brands, Inc.. (NASDAQ: TLRY) shares climbed in Thursday's extended trading after the company released its second-quarter earnings report, beating expectations on the top and bottom lines.
Tilray Brands Delivers Record Q2 Fiscal 2026 Net Revenue of $218 Million, Moves to Net Cash Position and Reaffirms Full-Year Adjusted EBITDA Guidance
International Medical Cannabis Revenue Increases 36%; Canadian Adult-Use Cannabis Revenue Grows 6% Tilray Pharma Achieves Record Quarterly Revenue U.S. Federal Cannabis Rescheduling Expected to Unlock...
Top Wall Street Forecasters Revamp Tilray Brands Expectations Ahead Of Q2 Earnings
Tilray Brands, Inc. (NASDAQ: TLRY) will release earnings results for its second quarter after the closing bell on Thursday, Jan. 8, 2025.
Tilray Q2: High Hopes or Harsh Reality?
As Canadian cannabis king Tilray Brands, Inc. (NASDAQ: TLRY) prepares to report its fiscal Q2 2026 results on Thursday, the company stands at a crossroads.
Best Canadian Cannabis Stocks to Watch Entering 2026
The cannabis industry continues to evolve as investors look toward 2026 with renewed optimism. Canadian cannabis companies remain at the center of global expansion. They benefit from strong medical pr...
Tilray stock forms a risky pattern: Jan. 8 will be key
Tilray stock price has been highly volatile in the past few months as investors focused on Donald Trump's cannabis reclassification efforts and its implications. It surged from $3.59 in June to a high...
Tilray Brands Expands Dry January Offerings with Zero-Proof Spirits, Non-Alcoholic Beers and Hemp-Derived THC Beverages
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellnes...
Top Stocks With Earnings This Week: Tilray, Applied Digital and More
As the first full week of 2026 kicks off, the earnings calendar features a mix of early reports in the cannabis, AI infrastructure and consumer goods sectors.
Enhance Your Dry January with Mindful Sipping: Try Tilray's Mollo and XMG Cannabis Beverages
TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellnes...
Trump Is Warming to Cannabis, but Investors Aren't Impressed
Stocks took a surprise tumble after the White House moved to reclassify marijuana as a less dangerous drug.
Marijuana Stocks To Watch After The Holidays
In 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. Whi...
Is Tilray Stock's 25% Drop An Opportunity Or Trap?
Tilray Brands (TLRY) stock has declined by 25.3% in under a month, decreasing from $13.94 on 16th Dec, 2025 to $10.53 currently. Is it time to purchase this dip?
Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026
NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at...
Inside the dealmaking that pushed Trump to reclassify pot, expand access
President Donald Trump's marijuana reclassification executive order followed a yearlong push by cannabis executives, billionaire allies and political operatives combining donations, lobbying and targe...
After Trump's move to reclassify cannabis, here's what Wall Street is thinking
Analysts are now focused on the when the change will actually happen, as the cannabis industry waits for tax relief and expanded research opportunities.
Trump signs executive order to reschedule cannabis. Here's what's next
Trump's executive order shifts cannabis from Schedule I to Schedule III, and launches a Medicare pilot program for CBD products. Brandon Gomez unpacks what's next, the hurdles ahead and what shifted t...
Trump just legalized marijuana nationwide — here's why potheads are rejoicing
As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal gov...
Trump sparks market shock with MAJOR marijuana move
Rep. Greg Steube, R-Fla., joins ‘Mornings with Maria' to discuss cutting healthcare costs, the fight over Obamacare subsidies and shutdown risks, President Donald Trump's marijuana order and the GOP's...
Former WH drug policy advisor: Mass commercialization and promotion of marijuana isn't a good thing
Kevin Sabet, Smart Approaches to Marijuana CEO, former White House drug policy advisor and ‘One Nation Under Influence' author, joins 'Squawk Box' to discuss President Trump's executive order to recla...
Why US banks are still wary of cannabis despite Trump's policy shift
President Donald Trump's move to relax federal marijuana regulations has been welcomed by the US cannabis industry, but it has not changed the sector's most persistent challenge. Access to mainstream ...
How Trump's marijuana reclassification could impact medical research
Scotts Miracle-Gro CEO James Hagedorn discusses President Donald Trump signing an executive order to reclassify marijuana on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #brea...
Cannabis companies face hurdles accessing big banks despite reclassification, experts say
U.S. President Donald Trump's move to relax marijuana regulations could ease some burden for cannabis companies, but will likely keep doors to access capital from big banks closed, experts said.